SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism …

Most antibodies isolated from individuals with coronavirus disease 2019 (COVID-19) are
specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However …

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
caused a public health crisis that is exacerbated by our poor understanding of correlates of …

We investigated the temporal profile of multiple components of the serological response
after asymptomatic or mildly symptomatic SARS-CoV-2 infection, in a cohort of 67 previously …

Antibodies perform both neutralizing and non-neutralizing effector functions that protect
against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 …

Although SARS-CoV-2-neutralizing antibodies are promising therapeutics against COVID-
19, little is known about their mechanism (s) of action or effective dosing windows. We report …

Neutralizing monoclonal antibodies (nAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) represent promising candidates for clinical intervention against …

A fraction of COVID-19 convalescent individuals mount a potent antibody response to SARS-
CoV-2 with cross-reactivity to SARS-CoV-1. To uncover their humoral response in detail, we …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health …

Antibodies against coronavirus spike protein potently protect against infection and disease,
but whether such protection can be extended to variant coronaviruses is unclear. This is …